Biologic agents for rheumatoid arthritis-negotiating the NICE technology appraisals

Rheumatology

Volumn 51, Issue 1, 2012, Pages 24-31

  Kiely, Patrick D W ^a   Deighton, Chris ^b   Dixey, Josh ^c   Östör, Andrew J K ^d  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEW CROSS HOSPITAL   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Abatacept; Adalimumab; Biologic agents; Certolizumab pegol; Etanercept; Guidelines; Rheumatoid arthritis; Rituximab; TNF antagonists; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB;

ALCOHOL LIVER DISEASE; BIOLOGICAL THERAPY; BLOOD DYSCRASIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; INFECTION; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TUBERCULOSIS; VASCULITIS;

ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84855182295     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker321     Document Type: Review

References (30)

1. Kiely PDW, Brown AK, Edwards CJ et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009;48:765-72.
2. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69: 631-7.
3. NICE TA 130. http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf.
4. NICE TA 186. http://www.nice.org.uk/nicemedia/live/12808/47544/47544.pdf.
5. NICE TA 195. http://www.nice.org.uk/nicemedia/live/13108/50413/50413.pdf.
6. NICE TA 198. http://www.nice.org.uk/nicemedia/live/13100/50391/50391.pdf.
7. Irish guidelines. http://www.isr.ie/-fileupload/File/ISR%20Guidelines%20A4%20(3).pdf.
8. Fautrel B, Pham T, Mouterde G et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007;74:627-37.
9. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
10. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
11. Deighton C, Hyrich K, Ding T et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010;49:1197-9.
12. Kiely P, Walsh D, Williams R, Young A; for the Early Rheumatoid Arthritis Network. Outcome in RA patients with continued conventional therapy for moderate disease activity. The Early Rheumatoid Arhtritis Network (ERAN). Rheumatology 2011;50:926-31.
13. Klareskog L, van der Heidje D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compatred with each treatment alone in patients with rheumatoid arthritis: double blind randomised controlled trial. Lancet 2004;363:675-81.
14. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who have not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
15. Hyrich KL, Watson KD, Lunt M, Symmons DPM; on behalf of BSR Biologics Register. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 2011;50:117-23.
16. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Joint Dis 2008;66:77-85.
17. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69: 88-96.
18. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy (TOWARD) study. Arthritis Rheum 2008;58:2968-80.
19. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
20. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active Rheumatoid arthritis. A randomized trial. Arthritis Rheum 2008;58:953-63.
21. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
22. Emery P, Keystone E, Tony H-P et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23.
23. Cohen SB, Emery P, Greenwald MW et al.; for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54: 2793-806.
24. Silverman GJ, Schwartzman S, Townsend M et al. Identification of biomarkers for enhanced benefit to rituximab in rheumatoid arthritis: role of autoantibodies and inflammatory markers. Arthritis Rheum 2009; 60(Suppl. 10):1680.
25. Isaacs J, Olech E, Tak P et al. Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab when compared to seronegative patients. Ann Rheum Dis 2009;68(Suppl. 3): 442.
26. Genovese MC, Becker J-C, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
27. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomised, double-blind, placebocontrolled, phase III trial. Lancet 2009;374:210-21.
28. Buch MH, Saleem B, Das S et al. Abatacept therapy is associated with minimal attrition rate irrespective of rheumatoid factor status in patients with highly resistant rheumatoid arthritis. Ann Rheum Dis 2010; 69(Suppl. 3):378.
29. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 2006;54:1390-400.
30. Campbell L, Chen C, Bhagat SS et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50: 552-62.